1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Nextgen Biomed Ltd

Nextgen Biomed Ltd

NXGN.TA
Nextgen Biomed LtdIL flagTel Aviv Stock Exchange
47.00
ILA
-2.00
- -
5.12MMarket Cap
Nextgen Biomed Ltd
NXGN.TA
(Tel Aviv Stock Exchange)

Recent

price

47.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
1
1
3
5
5
5
5
7
7
7
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-8
-5
-4
-2
-1
-1
-1
-1
-3
-9
-14
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
-1
2
5
4
2
1
7
21
12
-1
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
47.46%
137.89%
151.79%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
23.25%
67.94%
-65.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
DENTSPLY SIRONA Inc. (DY2.F)
NEXGEL, Inc. (NXGLW)
LifePoint, Inc. (LFPI)
KMA Holding, Inc. (MCDA)
Femasys Inc. (FEMY)
Azenta, Inc. (AZTA)
Business
Nextgen Biomed Ltd Nextgen Biomed Ltd (NXGN.TA) is an Israel-based biotechnology company focused on developing innovative medical devices and topical treatments for chronic conditions. Incorporated in 1990 and headquartered at 132 Azrieli Towers Round Building in Tel Aviv, Israel, with additional presence at Prof. Hillel ve-Khanan Oppenheimer St 7 in Rehovot, the company primarily advances the EyePen system, a diabetes management device comprising an injection module integrated with a mobile app to monitor insulin doses, timing, and user behavior while providing alerts for errors such as forgotten, doubled, or skipped injections; it also develops topical treatments for psoriasis targeting dermatological applications. Nextgen Biomed Ltd, formerly known as Sela Group.Com Ltd, underwent a name change in February 2010 to reflect its shift toward biomedical research and development in the healthcare sector, serving patients with diabetes and skin disorders through systematic monitoring and therapeutic solutions; the firm maintains a lean operation with three employees under CEO Harel Hershtik and lists on the Tel Aviv Stock Exchange with ISIN IL0010839301.